Statins in liver disease: a molehill, an iceberg, or neither? - Wikidata - wikimedia - TriplyDB

Statins in liver disease: a molehill, an iceberg, or neither?

Statins in liver disease: a molehill, an iceberg, or neither?

http://www.wikidata.org/entity/Q30446668

about

Statins and its hepatic effects: Newer data, implications, and changing recommendations Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step Statins for primary cardiovascular prevention in the elderly Strategies to rescue steatotic livers before transplantation in clinical and experimental studies Statin associated hepatic adverse effects: a retrospective review from a regional hospital in sultanate of oman Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.Pitavastatin suppresses diethylnitrosamine-induced liver preneoplasms in male C57BL/KsJ-db/db obese mice.Safety of statins: an update Nonalcoholic fatty liver disease and aging: epidemiology to management.Statin use in patients with cirrhosis: a retrospective cohort study.Treating statin-intolerant patients An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).Beneficial Effects of Statins on the Rates of Hepatic Fibrosis, Hepatic Decompensation, and Mortality in Chronic Liver Disease: A Systematic Review and Meta-Analysis.Nonalcoholic fatty liver disease and cardiovascular risk.Management of statin intolerance Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.Expert opinion on current therapies for nonalcoholic fatty liver disease.Clinical perspective: statins and the liver--harmful or helpful?Potential for statins in the chemoprevention and management of hepatocellular carcinoma.Towards companion diagnostics for the management of statin therapy.Primary prevention of cardiovascular disease with statins in the elderly.Diagnosis and management of cardiovascular risk in nonalcoholic fatty liver disease.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.NASH Therapy: omega 3 supplementation, vitamin E, insulin sensitizers and statin drugs.Pharmacogenomic and personalized approaches to tackle nonalcoholic fatty liver disease.Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.Lovastatin interacts with natural products to influence cultured hepatocarcinoma cell (hep-g2) growth.ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic-therapeutic pathway in Italy.Nonalcoholic fatty liver disease: from lipid profile to treatment.ANMCO Position Paper: diagnostic-therapeutic pathway in patients with hypercholesterolaemia and statin intolerance Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome.Bioenergetic study of murine hepatic tissue treated in vitro with atorvastatin Rosuvastatin counteracts vessel arterialisation and sinusoid capillarisation, reduces tumour growth, and prolongs survival in murine hepatocellular carcinoma.Dietary capsaicin prevents nonalcoholic fatty liver disease through transient receptor potential vanilloid 1-mediated peroxisome proliferator-activated receptor δ activation.Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial.Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.Prescribing a statin to a cirrhotic patient to reduce hepatic decompensation and improve survival: impossible you say?

P2860

Q26767065-77EDCBE8-8896-405C-8620-60AAF962DBE8 Q26771518-0C2D7F50-9438-4750-9535-336DA83401F7 Q26783401-35B931C2-CFFC-4EF2-B8E1-4324E6536EC4 Q27003912-4AEB2CD5-150E-49A6-AAD7-230575E19B41 Q28654581-EDDC602D-B954-40E1-A4B4-F9EBAFD5DB33 Q33765060-0531F290-A81F-4FA3-8885-3956F5B20CBC Q33944911-A8160767-D76B-4A35-A971-02098621985E Q33949312-9BC201B0-95F9-43C3-A319-54E6BC4036B7 Q34366861-0DDF90DB-10F9-40C2-B711-2EC1A9115CAF Q34661975-39CA9575-FF7B-4B34-B61A-F28E01C316BA Q35110510-18695E8D-7F1A-442D-AF71-B8B9D902E6B2 Q36328050-A559F70A-0ED8-41A4-A9BF-EFAA7CE5C189 Q36393781-169B5BC9-F113-4907-97A8-D6EB2C68FC60 Q37318761-44184754-B07E-4941-B522-4B1FCCB5E2DF Q37414000-9F410225-3EB7-40CA-8480-8374435ACD76 Q37847181-08A98248-5C84-496D-BF97-3D824F0E4E54 Q37884620-5B8FC1AD-5ECA-408A-8C04-2F5B9FB156FC Q38009719-4803E35D-CF23-489E-A2F4-9F2BEE3F0706 Q38030991-7583365C-33BD-4856-A31F-EEC4675B7E2C Q38089842-3351CB75-41DC-472E-8613-21AA532FA0E1 Q38208222-A66ABD9F-3143-4AEF-997A-6CAA4921629E Q38261236-33A9D965-8C60-4AED-A0AC-9C501DD33AEE Q38782562-33D84C09-0C94-4FC7-8FE1-E39FD8AD04BD Q38791719-A383C751-04DA-4F26-9762-C6950E118FD5 Q38845334-12E785BF-8210-4B57-A710-2CBE6FF92C0D Q38890066-40030F25-9FE8-4548-966C-F5ACBCE984B0 Q39656742-E07ABF32-B54F-4217-9596-757BB9CF5B54 Q40104818-00A32B3C-7463-4B30-AC0E-5AFE9017EBC9 Q40729988-D5D38CB2-4298-4FD3-92A9-EACFA575C12A Q41082961-7BC0104C-442F-484E-8DD7-2F42814457A5 Q41093207-AA44E877-B800-420D-9574-300679B904D4 Q42160233-9FD48ADE-6AF8-4E2B-B989-1D30B0E1EFC8 Q42721917-496B0017-BE5E-490D-8132-9388228A1B73 Q44206097-3FEA3E8F-696A-4B81-AF31-0EE3421BC693 Q47868469-2BF41AD6-F1F0-4561-9FB6-0386212CC85B Q53272521-77ECFC64-848C-4AFE-8A70-AADC2A6E9312 Q55058377-2C7745F3-AE48-4B72-AD07-774804A9DDFF

P2860

Statins in liver disease: a molehill, an iceberg, or neither?

http://www.wikidata.org/entity/Q30446668

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Statins in liver disease: a molehill, an iceberg, or neither?

@ast

Statins in liver disease: a molehill, an iceberg, or neither?

@en

type

label

Statins in liver disease: a molehill, an iceberg, or neither?

@ast

Statins in liver disease: a molehill, an iceberg, or neither?

@en

prefLabel

Statins in liver disease: a molehill, an iceberg, or neither?

@ast

Statins in liver disease: a molehill, an iceberg, or neither?

@en

P1433

Q30446668-A81DBD59-17D3-4667-AA23-C23501567599

P1476

Q30446668-05B77220-86DE-46A3-AB82-E3525DF554D4

P2093

Q30446668-18FA1EE4-AE01-4B25-A25F-022A75F287A0

Q30446668-3BEDCE67-6BBE-4CFD-B6FD-44698E4A812A

Q30446668-DD3A4DA8-FF7F-419C-8202-9BEF22AD209B

P2860

Q30446668-344D21FB-9719-468B-A869-B3DF1F559F02

Q30446668-53C86C80-2926-40D5-90A6-AD14974921D4

Q30446668-998BF824-D28A-492D-9247-3EAAEFD82419

Q30446668-99977894-2B0A-4ABB-AF76-0DF5D6BC9DD3

P304

Q30446668-E502EDCB-C58D-47BE-9463-1828AECB9ED8

P31

Q30446668-AD013A56-BBC1-46A5-9C62-47BC50C7F501

P356

Q30446668-3FCDB350-F11B-4330-A967-4A0162355EF4

P407

Q30446668-8A06A644-43AA-4E2C-8DA5-DD8AF0FA33C1

P433

Q30446668-0D44772E-9496-408A-A128-A6385F034ADC

P478

Q30446668-DA3A671E-6D0C-450E-80A9-4B0EA2BB6426

P50

Q30446668-C9122F37-F11E-40D9-A755-EF31B6FEFB28

P577

Q30446668-86405CD8-2FD0-4CCE-ADCD-EFA2901A2885

P5875

Q30446668-6539A9CA-3C27-4DF4-AA36-E9522FCE639E

P698

Q30446668-D9A794EA-AE1A-4FC0-A77E-6C5EC26BB572

P921

Q30446668-892066A7-94E0-4AA9-8002-A1C0EABCEF2B

P356

P1433

P1476

Statins in liver disease: a molehill, an iceberg, or neither?

@en

P2093

Curtis K Argo

http://www.w3.org/2001/XMLSchema#string

Paola Loria

http://www.w3.org/2001/XMLSchema#string

Stephen H Caldwell

http://www.w3.org/2001/XMLSchema#string

P2860

SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.

Updated definitions of healthy ranges for serum alanine aminotransferase levels.

Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis.

P304

662-669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.22402

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23136669

http://www.w3.org/2001/XMLSchema#string

P698

18666246

http://www.w3.org/2001/XMLSchema#string

P921